Larimar Therapeutics

Yahoo Finance • last month

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of... Full story

Yahoo Finance • 5 months ago

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or “the Company”... Full story

Yahoo Finance • 6 months ago

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL study Increases in skin FXN... Full story

Yahoo Finance • 6 months ago

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company... Full story

Yahoo Finance • 7 months ago

TNA: ETF Outflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily Small Cap Bull 3X Shares (Symbol: TNA) where we have detected an approximate $88.7 million dol... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics GAAP EPS of -$0.41 beats by $0.07

* Larimar Therapeutics press release [https://seekingalpha.com/pr/20200727-larimar-therapeutics-reports-second-quarter-2025-financial-results] (NASDAQ:LRMR [https://seekingalpha.com/symbol/LRMR]): Q2 GAAP EPS of -$0.41 beats by $0.07.... Full story

Yahoo Finance • 8 months ago

Insider Activity Recap: Top Buys and Sells from Monday, August 4, 2025

This article summarizes the most significant insider buying and selling activities reported for US stocks on Monday, August 4, 2025. Top Insider Buys: CVB Financial Corp (NASDAQ:CVBF): Director George A. Borba Jr. of CVB Financial Corp... Full story

Yahoo Finance • 8 months ago

Larimar therapeutics: Deerfield funds buy $10.8m in shares

On July 31, 2025, several Deerfield entities, including Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Healthcare Innovations Fund, L.P., purchased shares of Larimar Therapeutics, Inc. (NASDA... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics prices $60M stock offering

* Larimar Therapeutics (NASDAQ:LRMR [https://seekingalpha.com/symbol/LRMR]) has priced its underwritten public offering of 18.75 million shares at $3.20 per share, expecting to raise $60 million in gross proceeds. * The company has als... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics prices public offering at $3.20 per share

BALA CYNWYD, Pa. - Larimar Therapeutics, Inc. (NASDAQ:LRMR), currently trading at $3.53 with a market capitalization of $226 million, has priced its underwritten public offering of 18,750,000 shares of common stock at $3.20 per share, the... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of... Full story

Yahoo Finance • 8 months ago

What's going on in today's after hours session

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics drops 20% as it announces public offering

* Larimar Therapeutics (NASDAQ:LRMR [https://seekingalpha.com/symbol/LRMR]) said on Tuesday that it has commenced an underwritten public offering [https://seekingalpha.com/pr/20181713-larimar-therapeutics-announces-proposed-underwritten-... Full story

Yahoo Finance • 8 months ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has com... Full story

Yahoo Finance • 9 months ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated appr... Full story

Yahoo Finance • 9 months ago

Larimar Therapeutics soars 70% after April fair value signal

Investing.com’s Fair Value analysis has once again demonstrated its effectiveness in identifying undervalued opportunities, with Larimar Therapeutics (NASDAQ:LRMR) delivering a remarkable 70% return in just over two months. While past perf... Full story

Yahoo Finance • 10 months ago

Guggenheim reiterates buy rating on Larimar stock citing FDA path clarity

Investing.com - Guggenheim maintained its Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ:LRMR) following management meetings in New York. The firm highlighted that FDA safety requirements for Larimar’s nomlabofusp are... Full story

Yahoo Finance • 10 months ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company... Full story

Yahoo Finance • 11 months ago

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article. Wall Street analysts believe LRMR has a 957% upside poten... Full story